Colostrum feeding

PreclinicalBiologic

CCentre Hospitalier Universitaire de Nice

Colostrum feeding is one of 8 biologic programs targeting Amenorrhea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AmenorrheaActive, not recruiting

AmenorrheaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Amenorrhea

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

2 2

Zometa

Pfizer

Phase 3

1 3

Romosozumab

Amgen

Phase 3

1 4

Mibavademab

Regeneron

Phase 2

1 5

Cytotec

Pfizer

Preclinical

1 6

Kisspeptin

MMassachusetts General Hospital

Phase 2

1 7

Kisspeptin 112-121

SStephanie B. Seminara, MD

Phase 2

1 8

Colostrum feeding

CCentre Hospitalier Universitaire de Nice

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amenorrhea1 trial

Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea

Completed·—·N/A·NCT02650167·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Colostrum feeding. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Colostrum feeding compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Colostrum feeding. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Nice company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire de Nice

Colostrum feeding

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amenorrhea1 trial

References

Drug Info

Quick Facts

Related News